Rheumatology International
Leading citation impact metric from Clarivate Journal Citation Reports
66 papers with at least that number of citations each
State Council for Professorship (HĐGSNN) Scoring
Quyết định số 26/QĐ-HĐGSNN ngày 11/7/2025 (Mục quốc tế)
HĐGSNN Score History
By article publication year| Year | Max Score | Evaluation Details | Source |
|---|---|---|---|
| 2026 | 1.75đ | WoS Q2 có IF ≥ 2.0(IF: 3.5) | 🔵 Computed |
| 2025 | 1.75đ | WoS Q2 có IF ≥ 2.0(IF: 2.9) | 🔵 Computed |
| 2024 | 1.75đ | WoS Q2 có IF ≥ 2.0(IF: 3.2) | 🔵 Computed |
| 2023 | 1.75đ | WoS Q2 có IF ≥ 2.0(IF: 4) | 🔵 Computed |
| 2022 | 1.75đ | WoS Q2 có IF ≥ 2.0(IF: 3.58) | 🔵 Computed |
| 2021 | 1.75đ | WoS Q2 có IF ≥ 2.0(IF: 2.631) | 🔵 Computed |
| 2020 | 1.50đ | WoS Q2(IF: 1.984) | 🔵 Computed |
| 2019 | 1.75đ | WoS Q2 có IF ≥ 2.0(IF: 2.2) | 🔵 Computed |
| 2018 | 1.50đ | WoS Q2(IF: 1.952) | 🔵 Computed |
Note: Domestic journal scores are officially collected from annual HĐGSNN decisions across councils. International journal scores are dynamically computed according to Decision 26/QĐ-HĐGSNN based on quartile and citation metrics in the publication year.
Aims & Scope
RHEUMATOLOGY INTERNATIONAL is an independent journal reflecting world-wide progress in the research, diagnosis and treatment of the various rheumatic diseases. It is designed to serve researchers and clinicians in the field of rheumatology. RHEUMATOLOGY INTERNATIONAL will cover all modern trends in clinical research as well as in the management of rheumatic diseases. Special emphasis will be given to public health issues related to rheumatic diseases, applying rheumatology research to clinical practice, epidemiology of rheumatic diseases, diagnostic tests for rheumatic diseases, patient reported outcomes (PROs) in rheumatology and evidence on education of rheumatology. Contributions to these topics will appear in the form of original publications, short communications, editorials, and reviews. "Letters to the editor" will be welcome as an enhancement to discussion. Basic science research, including in vitro or animal studies, is discouraged to submit, as we will only review studies on humans with an epidemological or clinical perspective. Case reports without a proper review of the literatura (Case-based Reviews) will not be published. Every effort will be made to ensure speed of publication while maintaining a high standard of contents and production. Manuscripts submitted for publication must contain a statement to the effect that all human studies have been reviewed by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in an appropriate version of the 1964 Declaration of Helsinki. It should also be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted.
SCImago & Scopus Journal Intelligence
Global SCImago ranking, SJR prestige index, Scopus coverage, and societal policy impact
Weighted prestige citation metric per document indexed in the Scopus database.
Measures cumulative publication volume and citation impact.
Average citations received per document published in the 2-year window.
Estimated Article Processing Charge for Open Access publication.
Scopus 3-Year Publication & Citation Window
Aggregated from Scopus database across the 3-year SJR evaluation window.
Societal Impact & Inclusivity (SCImago)
Citations in government and international policy documents
Percentage of female authors published in the journal
Real-world societal policy reach and author gender diversity tracked by SCImago.
Scopus Subject Categories
Chinese Academy of Sciences (CAS) Classification
Major / minor zone classification and CAS Early Warning List history
Publishing & Editorial Information
Detailed publisher, peer-review turnaround, and publication cycle specifications
WoS Categories & Quartiles
Detailed JCR / JCI category rankings and quartile breakdown from Clarivate
| Category | Index | Rank | Quartile |
|---|---|---|---|
RHEUMATOLOGY | JCRSCIE | 18/58 | Q2 |
RHEUMATOLOGY | JCISCIE | 22/58 | Q2 |
Annual Historical Statistics & Publications
Track annual publication volume, total citations, and Impact Factor evolution
| Year | Impact Factor | Articles / Year | Total Citations |
|---|---|---|---|
| 2026 | — | 236 | 103 |
| 2025 | 2.9 | 294 | 1,046 |
| 2024 | 3.2 | 247 | 1,764 |
| 2023 | 4 | 249 | 2,587 |
| 2022 | 3.58 | 202 | 2,825 |
| 2021 | 2.631 | 301 | 6,198 |
| 2020 | 1.984 | 252 | 6,254 |
| 2019 | 2.2 | 275 | 6,372 |
| 2018 | 1.952 | 307 | 6,584 |
| 2017 | — | 278 | 7,447 |
| 2016 | — | 226 | 6,444 |
| 2015 | — | 209 | 4,846 |
Journal Metrics & Citation Visualizations
Impact Factor Trend (2018–2024)
Clarivate IF trend for Rheumatology International
Total Cites vs Self-Cites
Evaluation of scholarly independence and citation reach
Citations per Document
Citation metric windows across 2, 3, and 4 years
Similar Journals in Discipline
Journals in the same research field with comparable impact metrics